News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Ceapro Inc. and NATEX Collaborate on PGX Technology Scale-Up
Wednesday, November 08, 2023Ceapro Inc has announced a technical collaboration with NATEX Prozesstechnologie GmbH a company based in Austria to accelerate the scaleup of its proprietary PGX Technology for commercial use
Toragen, Inc. Releases Positive Safety Update for First Cohort of Phase 1 Trial in Individuals with Human Papillomavirus-Induced Cancer
Tuesday, November 07, 2023Today Toragen Inc a San Diegobased biotechnology company specializing in the development of selective drugs for cancers caused by viruses has reported positive safety findings from Cohort of its Phase trial
AviadoBio Receives FDA IND Clearance and Fast Track Designation for AVB-101 in the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
Tuesday, November 07, 2023AviadoBio an innovative gene therapy company dedicated to developing groundbreaking treatments for neurodegenerative disorders has officially announced that the US Food and Drug Administration
Genevant Sciences and Novo Nordisk to Partner on Hemophilia A Gene Editing Treatment Development
Monday, November 06, 2023Genevant Sciences a prominent company specializing in nucleic acid delivery and holding an extensive lipid nanoparticle patent portfolio has announced a collaboration and nonexclusive licensing agreement with Novo Nordisk
Boehringer Ingelheim Reaches a Significant Milestone in Chronic Kidney Disease: Promising Phase II Trial Results with an Aldosterone Synthase Inhibitor in Conjunction with Empagliflozin
Saturday, November 04, 2023Boehringer Ingelheim has released encouraging Phase II data for their experimental compound BI an innovative selective aldosterone synthase inhibitor The results indicate a substantial reduction in albuminuria
QIAGEN and Element Biosciences Announce Partnership to Deliver Comprehensive Next-Generation Sequencing Workflows for the AVITI System
Friday, November 03, 2023QIAGEN and Element Biosciences have entered into a strategic partnership to provide comprehensive nextgeneration sequencing NGS workflows for the AVITI System a stateoftheart sequencing platform built on Elements
Inhalon Biopharma Broadens Therapeutic Horizons via Licensing of Human Metapneumovirus (hMPV) Antibodies from the University of Georgia
Thursday, November 02, 2023Inhalon Biopharma a clinicalstage company specializing in the development of an innovative inhaled antibody platform for the treatment of acute respiratory infections has recently entered into a licensing agreement with the University of Georgia
Cessation Therapeutics Granted FDA Fast Track Designation for CSX-1004 in Preventing Fentanyl and Fentanyl Analog Overdose
Wednesday, November 01, 2023Cessation Therapeutics Inc a clinicalstage biotechnology company focused on biologics targeting substances of abuse has announced that the US Food and Drug Administration granted Fast Track designation
IOnctura Granted FDA Clearance for IND Application of Roginolisib, a Novel Allosteric Modulator Targeting PI3Kδ
Wednesday, November 01, 2023IOnctura a biotechnology company in the clinical stage is dedicated to developing targeted therapies for cancer that disrupt crucial tumor survival pathways It has obtained approval from the US Food and Drug Administration
SparX Biopharmaceutical Granted FDA Authorization for IND Submission of SPX-303, an Innovative Anti-LILRB2/PD-L1 Antibody Medication for Human Trials
Tuesday, October 31, 2023SparX Biopharmaceutical Corp has achieved a significant milestone in the field of powered antibody therapies with the approval of its Investigational New Drug application for SPX by the US Food and Drug Administration
